{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:25:02Z","timestamp":1785252302496,"version":"3.55.0"},"reference-count":49,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Health &amp; Welfare","award":["HR20C0025"],"award-info":[{"award-number":["HR20C0025"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Most high-grade serous ovarian carcinomas (HGSOCs) involving the peritoneum are aggressive. Epidermal growth factor receptor 2 (HER2) is aberrantly activated in a variety of solid cancers. The HER2 status of a tumor is based on cytoplasmic membrane staining of an intracellular domain (ICD)-specific HER2 antibody. We compared four anti-HER2 antibodies in an immunohistochemical study of HGSOC with peritoneal dissemination. HER2 expression was assessed in peritoneal disseminated HGSOC specimens from 38 patients by immunohistochemistry using four different anti-HER2 antibodies (an ICD antibody (clone A0485), an extracellular domain (ECD) antibody (clone SP3), and two antibodies recognizing HER2 phosphorylated at tyrosine 877 or 1248 (pHER2Y877 and pHER2Y1248)). HER2 gene amplification was accessed by chromogenic in situ hybridization (CISH). The antibodies showed HER2 positivity as follows: 31.6% of cases (12\/38) with A0485, 26.3% (10\/38) with SP3, 7.9% (3\/38) with pHER2Y877, and 21.1% (8\/38) with pHER2Y1248. Fifteen out of thirty-eight (39.5%) cases were positive for at least one of the four HER2 antibodies. HER2 gene amplification was detected in 3\/19 cases. All four HER2 antibodies could be used for patient selection for anti-HER2 therapies. These findings raise the possibility of anti-HER2 therapeutic strategies for HGSOC with peritoneal dissemination.<\/jats:p>","DOI":"10.3390\/jcm11236963","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T06:04:36Z","timestamp":1669615476000},"page":"6963","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["HER2 Expression in Peritoneal Dissemination of High-Grade Serous Ovarian Carcinoma: A Comparative Study of Immunohistochemical Reactivity Using Four HER2 Antibodies"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8873-0021","authenticated-orcid":false,"given":"Min-Kyung","family":"Yeo","sequence":"first","affiliation":[{"name":"Department of Pathology, Chungnam National University School of Medicine, Chungnam National University Hospital, Daejeon 35015, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sup","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Chungnam National University School of Medicine, Chungnam National University Hospital, Daejeon 35015, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heon Jong","family":"Yoo","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Chungnam National University School of Medicine, Daejeon 35015, Republic of Korea"},{"name":"Department of Obstetrics and Gynecology, Chungnam National University Sejong Hospital, Sejong-si 30099, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3874-864X","authenticated-orcid":false,"given":"Kwang-Sun","family":"Suh","sequence":"additional","affiliation":[{"name":"Department of Pathology, Chungnam National University School of Medicine, Chungnam National University Hospital, Daejeon 35015, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0214-0296","authenticated-orcid":false,"given":"Kyung-Hee","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pathology, Chungnam National University School of Medicine, Chungnam National University Hospital, Daejeon 35015, Republic of Korea"},{"name":"Department of Pathology, Chungnam National University Sejong Hospital, Sejong-si 30099, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,25]]},"reference":[{"key":"ref_1","unstructured":"Soslow, R.A., Brebton, J.D., Davidson, B., Folkins, A.K., Kong, C.S., Malpica, A., Soerjomataram, I., and Vang, S.I.R. (2020). High-grade serous carcinoma of the ovary. WHO Classification of Tumours Editorial Board. Female Genital Tumours, International Agency for Research on Cancer. [5th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1038\/nm.2492","article-title":"Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth","volume":"17","author":"Nieman","year":"2011","journal-title":"Nat. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Kim, J., Park, E.Y., Kim, O., Schilder, J.M., Coffey, D.M., Cho, C.H., and Bast, R.C. (2018). Cell Origins of High-Grade Serous Ovarian Cancer. Cancers, 10.","DOI":"10.3390\/cancers10110433"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"16061","DOI":"10.1038\/nrdp.2016.61","article-title":"Ovarian cancer","volume":"2","author":"Matulonis","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Bartl, T., Karacs, J., Kreuzinger, C., Pfaffinger, S., Kendler, J., Ciocsirescu, C., Wolf, A., Reinthaller, A., Meyer, E., and Brandstetter, M. (2021). Tumor Growth Rate Estimates Are Independently Predictive of Therapy Response and Survival in Recurrent High-Grade Serous Ovarian Cancer Patients. Cancers, 13.","DOI":"10.3390\/cancers13051076"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1158\/1078-0432.CCR-18-2275","article-title":"Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer","volume":"25","author":"Johnson","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ygyno.2017.02.002","article-title":"Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance","volume":"145","author":"Schalper","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1200\/JCO.2005.05.4221","article-title":"Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: Potential predictive relationship with tumor HER2 activation status","volume":"24","author":"Gordon","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.molimm.2020.01.009","article-title":"A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action","volume":"119","author":"Zhang","year":"2020","journal-title":"Mol. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ejca.2005.11.012","article-title":"Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients","volume":"42","author":"Cicenas","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.4161\/cbt.29171","article-title":"Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition","volume":"15","author":"Dokmanovic","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"7163","DOI":"10.1038\/sj.onc.1210528","article-title":"ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines","volume":"26","author":"Ginestier","year":"2007","journal-title":"Oncogene"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Burguin, A., Furrer, D., Ouellette, G., Jacob, S., Diorio, C., and Durocher, F. (2020). Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0234991"},{"key":"ref_14","unstructured":"Amin, M., Edge, S., Greene, F.L., Byrd, D.R., Brookland, R.K., Washington, M.K., Gershenwald, J.E., Compton, C.C., Hess, K.R., and Sullivan, D.C. (2017). AJCC Cancer Staging Manual, Springer. [8th ed.]."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.21873\/anticanres.12792","article-title":"Nuclear Expression of CD133 Is Associated with Good Prognosis in Patients with Colorectal Adenocarcinoma","volume":"38","author":"Lee","year":"2018","journal-title":"Anticancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"618","DOI":"10.5858\/arpa.2014-0395-CP","article-title":"Template for Reporting Results of HER2 (ERBB2) Biomarker Testing of Specimens from Patients with Adenocarcinoma of the Stomach or Esophagogastric Junction","volume":"139","author":"Bartley","year":"2015","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/j.1365-2559.2011.04037.x","article-title":"Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing","volume":"59","author":"Hwang","year":"2011","journal-title":"Histopathology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/modpathol.3880582","article-title":"Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma","volume":"15","author":"Zhao","year":"2002","journal-title":"Mod. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1136\/jclinpath-2013-201647","article-title":"False positivity in HER2 testing of breast cancer: Novel paths for approaching an old dilemma","volume":"66","author":"Nunes","year":"2013","journal-title":"J. Clin. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/his.14419","article-title":"Analytical validation of human epidermal growth factor receptor 2 immunohistochemistry. by the use of the A0485 antibody versus the 4B5 antibody and breast versus gastric scoring guidelines in ovarian clear cell carcinoma","volume":"79","author":"Lin","year":"2021","journal-title":"Histopathology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/his.13704","article-title":"HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: Discordance between antibodies and with in-situ hybridisation","volume":"73","author":"Koopman","year":"2018","journal-title":"Histopathology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1158\/2159-8290.CD-12-0349","article-title":"Activating HER2 mutations in HER2 gene amplification negative breast cancer","volume":"3","author":"Bose","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"14476","DOI":"10.1073\/pnas.1203201109","article-title":"Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2","volume":"109","author":"Greulich","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ccr.2006.05.023","article-title":"HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors","volume":"10","author":"Wang","year":"2006","journal-title":"Cancer Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.2012.45.6095","article-title":"Lung cancer that harbors an HER2 mutation: Epidemiologic characteristics and therapeutic perspectives","volume":"31","author":"Mazieres","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"E6205","DOI":"10.1073\/pnas.1516853112","article-title":"HER2 missense mutations have distinct effects on oncogenic signaling and migration","volume":"112","author":"Zabransky","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12967-015-0476-2","article-title":"Oncogenic HER2 fusions in gastric cancer","volume":"13","author":"Yu","year":"2015","journal-title":"J. Transl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5687","DOI":"10.1158\/1078-0432.CCR-17-0900","article-title":"Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer","volume":"23","author":"Ma","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jtho.2015.10.025","article-title":"HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers","volume":"11","author":"Li","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/ajcp\/aqab117","article-title":"HER2-Low Breast Cancers","volume":"157","author":"Zhang","year":"2022","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"153229","DOI":"10.1016\/j.prp.2020.153229","article-title":"Intratumoral and intertumoral heterogeneity of HER2 immunohistochemical expression in gastric cancer","volume":"216","author":"Zhang","year":"2020","journal-title":"Pathol. Res. Pract."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13000-022-01230-7","article-title":"Dual block HER2 assessment increased HER2 immunohistochemistry positive rate in resected specimens of gastric cancer: A prospective multicenter clinical trial from China","volume":"17","author":"Xu","year":"2022","journal-title":"Diagn. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/PAI.0000000000000742","article-title":"Transferred-tissue Microarray for Fluorescence In Situ Hybridization Test for Human Epidermal Growth Factor Receptor 2 in Breast Cancer","volume":"28","author":"Lin","year":"2020","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1200\/JCO.19.01455","article-title":"NSABP B-47\/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy with or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2","volume":"38","author":"Fehrenbacher","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/PGP.0000000000000302","article-title":"Pattern of HER-2 Gene Amplification and Protein Expression in Benign, Borderline, and Malignant Ovarian Serous and Mucinous Neoplasms","volume":"36","author":"Mohammed","year":"2017","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_36","first-page":"635","article-title":"Expression of HER2\/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary","volume":"14","author":"Karaferic","year":"2009","journal-title":"J. BUON"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/modpathol.2008.108","article-title":"Immunophenotyping of serous carcinoma of the female genital tract","volume":"21","author":"Khalifa","year":"2008","journal-title":"Mod. Pathol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Lanitis, E., Dangaj, D., Hagemann, I.S., Song, D.G., Best, A., Sandaltzopoulos, R., Coukos, G., and Powell, D.J. (2012). Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0049829"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","article-title":"Ovarian cancer development and metastasis","volume":"177","author":"Lengyel","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Lisio, M.A., Fu, L., Goyeneche, A., Gao, Z.H., and Telleria, C. (2019). High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20040952"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Kim, S., Lee, Y., and Koo, J.S. (2015). Differential expression of lipid metabolism-related proteins in different breast cancer subtypes. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0119473"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"838652","DOI":"10.1155\/2015\/838652","article-title":"Docosahexaenoic Acid Modulates a HER2-Associated Lipogenic Phenotype, Induces Apoptosis, and Increases Trastuzumab Action in HER2-Overexpressing Breast Carcinoma Cells","volume":"2015","author":"Ravacci","year":"2015","journal-title":"BioMed Res. Int."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"375","DOI":"10.20892\/j.issn.2095-3941.2018.0062","article-title":"Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer","volume":"15","author":"Bonello","year":"2018","journal-title":"Cancer Biol. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"408","DOI":"10.4161\/cbt.19292","article-title":"Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells","volume":"13","author":"Ohta","year":"2012","journal-title":"Cancer Biol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ygyno.2010.05.005","article-title":"A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149)","volume":"118","author":"Hirte","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10637-013-9963-6","article-title":"Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors","volume":"32","author":"Tjulandin","year":"2014","journal-title":"Investig. New Drugs"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.2003.10.104","article-title":"Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group","volume":"21","author":"Bookman","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1535-6108(02)00097-1","article-title":"Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth","volume":"2","author":"Agus","year":"2002","journal-title":"Cancer Cell"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/23\/6963\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:27:06Z","timestamp":1760146026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/23\/6963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,25]]},"references-count":49,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["jcm11236963"],"URL":"https:\/\/doi.org\/10.3390\/jcm11236963","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,25]]}}}